Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation
- Conditions
- Interventions
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 90
- Registration Number
- NCT02112045
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure
- Conditions
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 56
- Registration Number
- NCT02105766
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
AML Therapy With Irradiated Allogeneic Cells
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Pure Erythroid Leukemia (M6b)Adult Acute Megakaryoblastic Leukemia (M7)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Erythroleukemia (M6a)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Interventions
- First Posted Date
- 2014-04-07
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 6
- Registration Number
- NCT02105116
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2017-07-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 100
- Registration Number
- NCT02098109
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-03-05
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 38
- Registration Number
- NCT02078102
- Locations
- 🇺🇸
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
- Conditions
- Interventions
- First Posted Date
- 2014-01-08
- Last Posted Date
- 2018-09-24
- Target Recruit Count
- 4
- Registration Number
- NCT02029638
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma
- First Posted Date
- 2014-01-06
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 60
- Registration Number
- NCT02027220
- Locations
- 🇨🇳
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
- Conditions
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 40
- Registration Number
- NCT02015013
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2015-01-14
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Registration Number
- NCT01940601
Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01938456
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.